TARA

Protara Therapeutics, Inc. [TARA] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

TARA Stock Summary

Top 10 Correlated ETFs

TARA


Top 10 Correlated Stocks

TARA


In the News

07:30 29 Sep 2023 TARA

Protara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

NEW YORK, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will present at the H.C. Wainwright 25th Annual Global Investment Conference on Monday, September 11, 2023, at 9:30 am ET in New York.

08:00 29 Sep 2023 TARA

Protara Therapeutics to Participate in Upcoming Investor Conferences

NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in the following upcoming investor conferences:

08:00 29 Sep 2023 TARA

Protara Therapeutics to Present at the Guggenheim Healthcare Talks Oncology Day

NEW YORK, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in a fireside chat at the Guggenheim Healthcare Talks Oncology Day on Thursday, February 9, 2023 at 11:20 am ET in New York, New York.

11:00 29 Sep 2023 TARA

Insider Buying 2022: 15 Stocks to Bet On Despite the Bear Market

In October 2021, I made a big call on Longeveron (NASDAQ: LGVN ) stock, a biotech firm working on a promising Alzheimer's therapy.

07:14 29 Sep 2023 TARA

Executives Buy Around $35M Of 4 Penny Stocks: Nextdoor, GreenLight Biosciences And More

The Dow Jones jumped by around 150 points on Monday. Investors, meanwhile, focused on some notable insider trades.

11:17 29 Sep 2023 TARA

Can Protara Therapeutics (TARA) Climb 680% to Reach the Level Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 680.4% in Protara Therapeutics (TARA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

08:00 29 Sep 2023 TARA

Protara Therapeutics to Participate in Upcoming Investor Conferences

NEW YORK, March 02, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in fireside chats at two upcoming virtual conferences:

08:00 29 Sep 2023 TARA

Protara Therapeutics to Present at the H.C. Wainwright BioConnect Virtual Conference

NEW YORK, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that management will present at the H.C. Wainwright BioConnect Virtual Conference being held from January 10-13, 2022.

05:57 29 Sep 2023 TARA

TARA Stock: Why The Price Increased This Past Week

The stock price of Protara Therapeutics Inc (NASDAQ: TARA) increased by over 5% during intraday trading. This is why it happened.

10:26 29 Sep 2023 TARA

Biopharma Stock Skyrockets on FDA Approval

Biopharmaceutical stock Protara Therapeutics Inc (NASDAQ:TARA) is surging today, up 11.9% to trade at $7.55 at last check.

TARA Financial details

Company Rating
Neutral
Market Cap
19.49M
Income
-65.92M
Revenue
0
Book val./share
7.54
Cash/share
7.11
Dividend
-
Dividend %
-
Employees
25
Optionable
No
Shortable
Yes
Earnings
01 Nov 2023
P/E
-0.29
Forward P/E
-
PEG
-0.07
P/S
-
P/B
0.22
P/C
0.23
P/FCF
-0.58
Quick Ratio
16.36
Current Ratio
17.09
Debt / Equity
0.07
LT Debt / Equity
0.06
-
-
EPS (TTM)
-5.85
EPS next Y
-
EPS next Q
-
EPS this Y
37.14%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
35.14%
-
-
-
-
SMA20
-
SMA50
-33.33%
SMA100
-33.33%
Inst Own
46.5%
Inst Trans
0.96%
ROA
-69%
ROE
-63%
ROC
-0.1%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
11.33M
Shs Float
6.27M
-
-
-
-
Target Price
-
52W Range
1.62-4.18
52W High
-58.38%
52W Low
+66.5%
RSI
29
Rel Volume
0.3
Avg Volume
27.47K
Volume
8.36K
Perf Week
-9.02%
Perf Month
-26.97%
Perf Quarter
-43.75%
Perf Half Y
-48.93%
-
-
-
-
Beta
1.49908
-
-
Volatility
0.03%, 0.22%
Prev Close
-0.89%
Price
1.665
Change
-2.63%

TARA Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
Revenue per share
00000
Net income per share
-9.93-2.52-4.63-4.2-5.76
Operating cash flow per share
-9.07-2.68-3.24-3.07-2.35
Free cash flow per share
-9.12-2.68-3.36-3.12-2.36
Cash per share
8.541.0623.318.127.49
Book value per share
7.981.0927.5414.419.07
Tangible book value per share
7.981.0923.4611.799.07
Share holders equity per share
7.981.0927.5414.419.07
Interest debt per share
000.150.640.67
Market cap
232.49M95.84M175.13M75.82M30.18M
Enterprise value
213.12M89.66M7.62M47.33M12.43M
P/E ratio
-9.14-6.51-5.23-1.61-0.47
Price to sales ratio
00000
POCF ratio
-10.01-6.13-7.48-2.2-1.14
PFCF ratio
-9.96-6.12-7.21-2.16-1.14
P/B Ratio
11.3714.990.880.470.3
PTB ratio
11.3714.990.880.470.3
EV to sales
00000
Enterprise value over EBITDA
-8.07-5.88-0.22-1-1.55
EV to operating cash flow
-9.17-5.73-0.33-1.37-0.47
EV to free cash flow
-9.13-5.72-0.31-1.35-0.47
Earnings yield
-0.11-0.15-0.19-0.62-2.15
Free cash flow yield
-0.1-0.16-0.14-0.46-0.88
Debt to equity
000.010.040.06
Debt to assets
000.010.040.06
Net debt to EBITDA
0.730.414.890.62.21
Current ratio
7.5511.9658.1321.6615.01
Interest coverage
0000-58.98
Income quality
1.121.040.690.730.4
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
000.150.170
Capex to operating cash flow
0.0100.040.020
Capex to revenue
00000
Capex to depreciation
-1.03-0.06-4.51-5.09-0.48
Stock based compensation to revenue
00000
Graham number
42.257.8853.5836.8934.27
ROIC
-1.54-2.34-0.17-0.27-0.57
Return on tangible assets
-1.08-2.11-0.19-0.33-0.57
Graham Net
7.340.9622.777.276.58
Working capital
20.16M6.39M166.52M88.81M80.41M
Tangible asset value
20.44M6.39M169.73M132.4M102.08M
Net current asset value
20.16M6.39M165.52M82.43M74.94M
Invested capital
000.010.040.06
Average receivables
000317K560K
Average payables
366K352K588.5K934K1.27M
Average inventory
000607.5K1.19M
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-1.24-2.3-0.17-0.29-0.63
Capex per share
-0.050-0.12-0.05-0.01

Quarterly Fundamentals Overview

Last date of statement is 2023-06-30 for Q2

Metric History 2022-06-302022-09-302022-12-312023-03-31 2023-06-30
Revenue per share
00000
Net income per share
-0.73-0.66-3.45-0.74-1
Operating cash flow per share
-0.46-0.47-0.45-1.14-0.83
Free cash flow per share
-0.46-0.48-0.45-1.14-0.83
Cash per share
8.758.557.497.667.11
Book value per share
12.9212.359.068.387.54
Tangible book value per share
10.39.739.068.387.54
Share holders equity per share
12.9212.359.068.387.54
Interest debt per share
0.640.610.580.480.52
Market cap
32.98M33.35M30.2M35.38M27.03M
Enterprise value
5.98M-7.55M12.45M20.51M-1.02M
P/E ratio
-1.01-1.13-0.19-1.06-0.6
Price to sales ratio
00000
POCF ratio
-6.44-6.24-6.01-2.75-2.87
PFCF ratio
-6.41-6.14-6-2.74-2.87
P/B Ratio
0.230.240.30.370.32
PTB ratio
0.230.240.30.370.32
EV to sales
00000
Enterprise value over EBITDA
-0.731.190.64-2.110.08
EV to operating cash flow
-1.171.41-2.48-1.590.11
EV to free cash flow
-1.161.39-2.47-1.590.11
Earnings yield
-0.25-0.22-1.29-0.24-0.42
Free cash flow yield
-0.16-0.16-0.17-0.36-0.35
Debt to equity
0.050.050.060.070.07
Debt to assets
0.040.040.060.060.06
Net debt to EBITDA
3.326.46-0.911.532.32
Current ratio
28.9426.5915.0114.7617.09
Interest coverage
-25.16-29.1191.3514.170
Income quality
0.60.70.131.420.83
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
0.190.2000
Capex to operating cash flow
00.02000
Capex to revenue
00000
Capex to depreciation
-0.38-0.080.01-0.08-0.03
Stock based compensation to revenue
00000
Graham number
14.5513.5226.5111.8113.01
ROIC
-0.05-0.050.18-0.08-0.12
Return on tangible assets
-0.07-0.06-0.34-0.08-0.12
Graham Net
7.927.746.586.646.41
Working capital
97.6M94.96M80.41M88.21M79.33M
Tangible asset value
115.94M109.66M102.08M94.77M85.23M
Net current asset value
91.67M89.25M74.94M82.98M74.35M
Invested capital
0.050.050.060.070.07
Average receivables
507.5K433.5K433K488.5K417.5K
Average payables
466.5K424K1.02M2.83M2.97M
Average inventory
1.04M-243.5K581.5K336K1.53M
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-0.06-0.05-0.38-0.09-0.13
Capex per share
0-0.01000

TARA Frequently Asked Questions

What is Protara Therapeutics, Inc. stock symbol ?

Protara Therapeutics, Inc. is a US stock , located in New york of Ny and trading under the symbol TARA

What is Protara Therapeutics, Inc. stock quote today ?

Protara Therapeutics, Inc. stock price is $1.665 today.

Is Protara Therapeutics, Inc. stock public?

Yes, Protara Therapeutics, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap